Challenges of Guarantee-Time Bias
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The potential for guarantee-time bias (GTB), also known as immortal time bias, exists whenever an analysis that is timed from enrollment or random assignment, such as disease-free or overall survival, is compared across groups defined by a classifying event occurring sometime during follow-up. The types of events associated with GTB are varied and may include the occurrence of objective disease response, onset of toxicity, or seroconversion. However, comparative analyses using these types of events as predictors are different from analyses using baseline characteristics that are specified completely before the occurrence of any outcome event. Recognizing the potential for GTB is not always straightforward, and it can be challenging to know when GTB is influencing the results of an analysis. This article defines GTB, provides examples of GTB from several published articles, and discusses three analytic techniques that can be used to remove the bias: conditional landmark analysis, extended Cox model, and inverse probability weighting. The strengths and limitations of each technique are presented. As an example, we explore the effect of bisphosphonate use on disease-free survival (DFS) using data from the BIG (Breast International Group) 1-98 randomized clinical trial. An analysis using a naive approach showed substantial benefit for patients who received bisphosphonate therapy. In contrast, analyses using the three methods known to remove GTB showed no statistical evidence of a reduction in risk of a DFS event with bisphosphonate therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
A generalization of sampling without replacement from a finite universe
Horvitz, D. G., & Thompson, D. J. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483446 · Cited by 4,293 · cited 1×
“IPW An alternative analytic approach uses IPW in a two-stage model and is based on methods that were originally developed to address survey nonresponse.(21) These methods have been extended to a variety of settings, such as those when interventions are modified during follow-up according to an individual’s changing he…”
Methodvon Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Analysis of survival by tumor response.
Anderson, J. R., Cain, K. C., & Gelber, R. D. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.11.710 · Cited by 1,107
Self-citationAnalysis of survival by tumor response.
Anderson, J. R., & Davis, R. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.115 · Cited by 1,000
Landmark Analysis at the 25-Year Landmark Point
Dafni, U. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957951 · Cited by 569
Curtis, L. H., Hammill, B. G., Eisenstein, E. L., Kramer, J. M., & Anstrom, K. J. (2007) · Medical Care · doi:10.1097/mlr.0b013e31806518ac · Cited by 494
Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments
Hernán, M. A., Brumback, B., & Robins, J. M. (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753168154 · Cited by 493
Marginal Mean Models for Dynamic Regimes
Murphy, S. A., van der Laan, M. J., Robins, J. M., & Conduct Problems Prevention Research Group (2001) · Journal of the American Statistical Association · doi:10.1198/016214501753382327 · Cited by 393
Research works printed but not linked: 3
- Shepherd LE, 2012, J Clin Oncol, 30, 7s
- 10.1200/JCO.2009.23.6000 · doi:10.1200/jco.2009.23.6000
- Van der Wal WM, 2011, J Stat Softw, 43, 1
Cited by
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02229 · Cited by 1,117
Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.04.014 · Cited by 1,097
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
Hua, C., Boussemart, L., Mateus, C., Routier, E., Boutros, C., Cazenave, H., Viollet, R., Thomas, M., Roy, S., Benannoune, N., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2707 · Cited by 655
Denkert, C., Seither, F., Schneeweiss, A., Link, T., Blohmer, J.-U., Just, M., Wimberger, P., Forberger, A., Tesch, H., Jackisch, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00301-6 · Cited by 552
Wolchok, J. D., Chiarion‐Sileni, V., Gonzalez, R. C., Grob, J., Rutkowski, P. L., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J. D., Dummer, R., et al. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-213514 · Cited by 550
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5246 · Cited by 497
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8545 · Cited by 484
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
Self-citationHodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1644 · Cited by 366
Transarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Azad, T. D., Chaudhuri, A. A., Fang, P., Qiao, Y., Esfahani, M. S., Chabon, J. J., Hamilton, E. G., Yang, Y. D., Lovejoy, A., Newman, A. M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.10.039 · Cited by 266
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., Furlanetto, J., Zahm, D.-M., Hanusch, C., Thomalla, J., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1940 · Cited by 262
Raschi, E., Gatti, M., Gelsomino, F., Ardizzoni, A., Poluzzi, E., & De Ponti, F. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00738-6 · Cited by 157
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150
“Sensitivity analyses were performed to control for immortal time bias (26) with regard to treatment.”
A Structural Description of Biases That Generate Immortal Time
Hernán, M. A., Sterne, J. A. C., Higgins, J. P. T., Shrier, I., & Hernández-Díaz, S. (2025) · Epidemiology · doi:10.1097/ede.0000000000001808 · Cited by 99
Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood · doi:10.1182/blood.2024024582 · Cited by 79
Survey on Machine Learning Biases and Mitigation Techniques
Siddique, S., Haque, M. A., George, R., Gupta, K. D., Gupta, D., & Faruk, M. J. H. (2023) · Digital · doi:10.3390/digital4010001 · Cited by 78
Metadata
- Authors
- Giobbie-Hurder, A., Gelber, R. D., & Regan, M. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-08-10
- Volume
- 31
- Issue
- 23
- Pages
- 2963-2969
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2110847259
- Cited by
- 458
- References
- 24
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.